No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,113 | 1,215 | 1,050 | 1,018 | 660 | 624 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 365 | 426 | 234 | 417 | -74 | -347 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating both domestically within the People's Republic of China and across international markets, Beijing SL Pharmaceutical Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of genetic engineering-based pharmaceuticals and associated medicinal products. Its extensive portfolio of finished pharmaceutical products encompasses a diverse range of medications, including but not limited to, temozolomide, arsenic trioxide, lenalidomide, docetaxel, paclitaxel, recombinant human granulocyte colony-stimulating factor (filgrastim), recombinant human interleukin-11, recombinant human interleukin-2, thymopentin, vinorelbine bitartrate, hydroxyl-camptothecine, nimustine hydrochloride, asparaginase, PEG L-asparaginase, calcium foliate, recombinant human basic fibroblast growth factor, ciclosporin, mycophenolate mofetil dispersible, ornidazole, adefovir dipivoxil, levofloxacin hydrochloride, azithromycin, ribavirin, tenofovir disoproxil fumarate, valacylovir hydrochloride, lysozyme, stavudine, tropisetron hydrochloride, granisetron hydrochloride, omeprazole, ademetionine 1,4-butanedisulfonate, glutathione, enoxaparin sodium, coenzyme complex, ginkgo biloba extract, simvastatin, telmisartan, naftopidil, nicergoline, zaleplon, cytidine disodium triphosphate, febuxostat, risedronate sodium, loratadine dispersible, somatostatin, octreotide acetate, calcitonin (salmon), the combination of paracetamol and tramadol hydrochloride, and etodolac. Furthermore, the company supplies active pharmaceutical ingredients (APIs). Established in Beijing, People's Republic of China, in 1994, the enterprise initially operated under the name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd. before officially adopting its current designation, Beijing SL Pharmaceutical Co., Ltd., in 1998.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating both domestically within the People's Republic of China and across international markets, Beijing SL Pharmaceutical Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of genetic engineering-based pharmaceuticals and associated medicinal products. Its extensive portfolio of finished pharmaceutical products encompasses a diverse range of medications, including but not limited to, temozolomide, arsenic trioxide, lenalidomide, docetaxel, paclitaxel, recombinant human granulocyte colony-stimulating factor (filgrastim), recombinant human interleukin-11, recombinant human interleukin-2, thymopentin, vinorelbine bitartrate, hydroxyl-camptothecine, nimustine hydrochloride, asparaginase, PEG L-asparaginase, calcium foliate, recombinant human basic fibroblast growth factor, ciclosporin, mycophenolate mofetil dispersible, ornidazole, adefovir dipivoxil, levofloxacin hydrochloride, azithromycin, ribavirin, tenofovir disoproxil fumarate, valacylovir hydrochloride, lysozyme, stavudine, tropisetron hydrochloride, granisetron hydrochloride, omeprazole, ademetionine 1,4-butanedisulfonate, glutathione, enoxaparin sodium, coenzyme complex, ginkgo biloba extract, simvastatin, telmisartan, naftopidil, nicergoline, zaleplon, cytidine disodium triphosphate, febuxostat, risedronate sodium, loratadine dispersible, somatostatin, octreotide acetate, calcitonin (salmon), the combination of paracetamol and tramadol hydrochloride, and etodolac. Furthermore, the company supplies active pharmaceutical ingredients (APIs). Established in Beijing, People's Republic of China, in 1994, the enterprise initially operated under the name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd. before officially adopting its current designation, Beijing SL Pharmaceutical Co., Ltd., in 1998.